• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Major Market Indices Performance Analysis for February 2025

  • February 25, 2025
  • Pharma & Biotech, Tech
Market Indices Performance Analysis for February 2025: Explore key trends in technology, energy, biotech, and pharmaceutical sectors and factors driving their shifts.
Continue Reading
VASRO GmbH

The Role of AI in Accelerating Drug Discovery: GSK’s $300 Million Partnership Explained

  • February 24, 2025
  • Pharma & Biotech, Tech
AI in pharmaceutical industry is revolutionizing drug discovery. GSK's $300M partnership with Relation Therapeutics accelerates treatments for osteoarthritis and fibrosis.
Continue Reading
VASRO GmbH

Pharma Giant Novo Nordisk Sues KBP Biosciences Over Ocedurenone Dispute

  • February 21, 2025
  • Pharma & Biotech
Novo Nordisk sues KBP Biosciences over alleged misrepresentation in the $1.3B ocedurenone deal, raising concerns about transparency in pharmaceutical transactions.
Continue Reading
VASRO GmbH

European Energy Stocks and Their Role in Shaping 2025 Market Trends

  • February 20, 2025
  • Unkategorisiert
European energy stocks, led by BP and Shell, are driving 2025 market trends with strategic shifts, influencing investor confidence and market stability.
Continue Reading
VASRO GmbH

Southeast Asia Stock Market Weekly Performance: Trends to Watch in 2025

  • February 19, 2025
  • Pharma & Biotech, Tech
Analyze the weekly performance of Southeast Asian stock markets, highlighting trends in biotech, energy, and technology sectors amid global economic shifts.
Continue Reading
VASRO GmbH

Market Reactions to China’s DeepSeek R1 AI Model Launch

  • February 18, 2025
  • Tech
China's DeepSeek R1 AI model launch caused market volatility, reshaped AI infrastructure strategies, and raised concerns over global tech investments.
Continue Reading
VASRO GmbH

Generative AI Success Stories in Drug Discovery

  • February 17, 2025
  • Pharma & Biotech, Tech
Generative AI is revolutionizing drug discovery and pharmaceutical R&D by accelerating timelines, reducing costs, and improving success rates with innovative solutions.
Continue Reading
VASRO GmbH

Why Equity Research Matters in the Era of AI Layoffs

  • February 14, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
AI layoffs and market shifts demand equity research to guide investors and companies. Discover how it identifies risks, opportunities, and ensures resilience.
Continue Reading
VASRO GmbH

A Comprehensive Guide to AI and Biotech Integration in 2025

  • February 13, 2025
  • Pharma & Biotech, Tech
Discover how the Biotech and Tech Industry Convergence in 2025 accelerates innovation, optimizes drug discovery, and ensures ethical AI governance.
Continue Reading
VASRO GmbH

Analyzing the Impact of Digitalization on Pharma in 2025

  • February 12, 2025
  • Pharma & Biotech, Tech
Discover how digital transformation is reshaping the pharma industry in 2025, driving innovation, efficiency, and aligning with Pharma Market Trends 2025.
Continue Reading

Posts pagination

Previous 1 … 25 26 27 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.